{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:50:41Z","timestamp":1768474241172,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Project code PE0000015, Concession Decree No. 1243 of 2 August 2022 adopted by the Italian Ministry of University and Research, CUP H33C22000680006, Project title \u201cAgeing well in an ageing society - A novel public-private alliance to generate socioeconomic, biomedical and technological solutions for an inclusive Italian ageing society\u2013 AGE-IT\"."],"award-info":[{"award-number":["Project code PE0000015, Concession Decree No. 1243 of 2 August 2022 adopted by the Italian Ministry of University and Research, CUP H33C22000680006, Project title \u201cAgeing well in an ageing society - A novel public-private alliance to generate socioeconomic, biomedical and technological solutions for an inclusive Italian ageing society\u2013 AGE-IT\"."]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["MIUR-PON \u201cR&I\u201d 2014\u20132020 \u201cBIOMIS\u201d cod.ARS01_01220"],"award-info":[{"award-number":["MIUR-PON \u201cR&I\u201d 2014\u20132020 \u201cBIOMIS\u201d cod.ARS01_01220"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009886","name":"Regione Puglia","doi-asserted-by":"publisher","award":["PON-AIM1853334, Attivit\u00e0 2- Linea 1"],"award-info":[{"award-number":["PON-AIM1853334, Attivit\u00e0 2- Linea 1"]}],"id":[{"id":"10.13039\/501100009886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009886","name":"Regione Puglia","doi-asserted-by":"publisher","award":["PON \u201cRICERCA E INNOVAZIONE\u201d 2014-2020 - Innovazione (D.M. 10 AGOSTO 2021, N. 1062)"],"award-info":[{"award-number":["PON \u201cRICERCA E INNOVAZIONE\u201d 2014-2020 - Innovazione (D.M. 10 AGOSTO 2021, N. 1062)"]}],"id":[{"id":"10.13039\/501100009886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC IG 2019 Id 23239"],"award-info":[{"award-number":["AIRC IG 2019 Id 23239"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-alcoholic fatty liver disease (NAFLD), specifically liver steatosis and fibrosis with steatohepatitis (NASH), is often associated with visceral adiposopathy, whose pathogenetic features have been proposed as tumorigenic triggers. We performed a prospective analysis in 653 metabolic women to reveal any conditions that may predict and concur to cancer development during a 8-years period of follow-up. Among clinical and biochemical variables, only AST and non-invasive liver fibrosis scores (AARPRI, APRI, FIB-4, mFIB4) significantly distinguished cancer-developer women (n\u2009=\u200962, 9.5%) from those who did not develop cancer (p\u2009&lt;\u20090.001). In ROC analysis, these scores also showed good sensitivity and specificity in differentiating women who developed cancer (all p\u2009&lt;\u20090.001). We then calculated OR for these indexes finding that increased AARPRI was associated with the highest risk (OR\u2009=\u20096, p\u2009&lt;\u20090.001) of gynaecological cancers development. We further validated these cut-off values in women who had developed other types of cancer, confirming that AARPRI is able to identify the risk for cancer development (OR\u2009=\u20095, p\u2009&lt;\u20090.001). Our findings support the hypothesis that NAFLD, more than obesity per se, is directly associated with the clinical and pathogenic metabolic scenario of gynaecological cancers and encourage the use of liver fibrosis indexes to detect risk of cancer onset in women. Preventing adiposopathy and NAFLD through lifestyle and therapies may represent an instrumental strategy for cancer prevention and\/or co-treatment in oncology.<\/jats:p>","DOI":"10.1038\/s41598-023-44243-y","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T17:01:56Z","timestamp":1697648516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["AST\/ALT-to-platelet ratio (AARPRI) predicts gynaecological cancers: a 8-years follow-up study in 653 women"],"prefix":"10.1038","volume":"13","author":[{"given":"Lucilla","family":"Crudele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"De Matteis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giusi","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Novielli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Petruzzelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Piccinin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella Maria","family":"Gadaleta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marica","family":"Cariello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"44243_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","volume":"400","author":"GBD 2019 Cancer Risk Factors Collaborators","year":"2022","unstructured":"GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010\u201319: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Lond. Engl. 400, 563\u2013591 (2022).","journal-title":"Lancet Lond. Engl."},{"key":"44243_CR2","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle, E. E., Rodriguez, C., Walker-Thurmond, K. & Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N. Engl. J. Med. 348, 1625\u20131638 (2003).","journal-title":"N. Engl. J. Med."},{"key":"44243_CR3","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1200\/JCO.2016.67.4051","volume":"34","author":"JA Ligibel","year":"2016","unstructured":"Ligibel, J. A. & Wollins, D. American society of clinical oncology obesity initiative: Rationale, progress, and future directions. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 34, 4256\u20134260 (2016).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"44243_CR4","doi-asserted-by":"publisher","first-page":"14834","DOI":"10.1038\/s41598-021-94277-3","volume":"11","author":"C De Matteis","year":"2021","unstructured":"De Matteis, C. et al. AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects. Sci. Rep. 11, 14834 (2021).","journal-title":"Sci. Rep."},{"key":"44243_CR5","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.3390\/jcm11185369","volume":"11","author":"L Crudele","year":"2022","unstructured":"Crudele, L. et al. Liver fibrosis indices predict the severity of SARS-CoV-2 infection. J. Clin. Med. 11, 5369 (2022).","journal-title":"J. Clin. Med."},{"key":"44243_CR6","doi-asserted-by":"publisher","first-page":"e0202393","DOI":"10.1371\/journal.pone.0202393","volume":"13","author":"N Peleg","year":"2018","unstructured":"Peleg, N. et al. Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PloS One 13, e0202393 (2018).","journal-title":"PloS One"},{"key":"44243_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"Berzigotti, A. et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J. Hepatol. 75, 659\u2013689 (2021).","journal-title":"J. Hepatol."},{"key":"44243_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","volume":"68","author":"G-A Kim","year":"2018","unstructured":"Kim, G.-A. et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J. Hepatol. 68, 140\u2013146 (2018).","journal-title":"J. Hepatol."},{"key":"44243_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cgh.2016.07.034","volume":"15","author":"JD Yang","year":"2017","unstructured":"Yang, J. D. et al. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 15, 127-131.e2 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"44243_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatol. Baltim. Md 65, 1557\u20131565 (2017).","journal-title":"Hepatol. Baltim. Md"},{"key":"44243_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","volume":"371","author":"AG Renehan","year":"2008","unstructured":"Renehan, A. G., Tyson, M., Egger, M., Heller, R. F. & Zwahlen, M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet Lond. Engl. 371, 569\u2013578 (2008).","journal-title":"Lancet Lond. Engl."},{"key":"44243_CR12","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/nu13062101","volume":"13","author":"L Crudele","year":"2021","unstructured":"Crudele, L., Piccinin, E. & Moschetta, A. Visceral adiposity and cancer: Role in pathogenesis and prognosis. Nutrients 13, 2101 (2021).","journal-title":"Nutrients"},{"key":"44243_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2015.03.002","volume":"21","author":"F Bovenga","year":"2015","unstructured":"Bovenga, F., Sabb\u00e0, C. & Moschetta, A. Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer. Cell Metab. 21, 517\u2013526 (2015).","journal-title":"Cell Metab."},{"key":"44243_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.plipres.2018.06.001","volume":"71","author":"M Pirro","year":"2018","unstructured":"Pirro, M. et al. High density lipoprotein cholesterol and cancer: Marker or causative?. Prog. Lipid Res. 71, 54\u201369 (2018).","journal-title":"Prog. Lipid Res."},{"key":"44243_CR15","doi-asserted-by":"publisher","first-page":"100627","DOI":"10.1016\/j.jhepr.2022.100627","volume":"5","author":"L Crudele","year":"2023","unstructured":"Crudele, L. et al. Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis. JHEP Rep. Innov. Hepatol. 5, 100627 (2023).","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"44243_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2016.11.024","volume":"32","author":"X Li","year":"2017","unstructured":"Li, X. et al. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. The Breast 32, 1\u20136 (2017).","journal-title":"The Breast"},{"key":"44243_CR17","doi-asserted-by":"publisher","first-page":"159087","DOI":"10.1016\/j.bbalip.2021.159087","volume":"1867","author":"J H\u00e4rdfeldt","year":"2022","unstructured":"H\u00e4rdfeldt, J. et al. Abdominal obesity negatively influences key metrics of reverse cholesterol transport. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1867, 159087 (2022).","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"44243_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12032-007-0034-8","volume":"24","author":"A Bilici","year":"2007","unstructured":"Bilici, A., Ozguroglu, M., Mihmanl\u0131, \u0130, Turna, H. & Adaletli, \u0130. A case\u2013control study of non-alcoholic fatty liver disease in breast cancer. Med. Oncol. 24, 367\u2013371 (2007).","journal-title":"Med. Oncol."},{"key":"44243_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","volume":"384","author":"K Bhaskaran","year":"2014","unstructured":"Bhaskaran, K. et al. Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5\u00b724 million UK adults. Lancet Lond. Engl. 384, 755\u2013765 (2014).","journal-title":"Lancet Lond. Engl."},{"key":"44243_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/curroncol30010005","volume":"30","author":"ES George","year":"2022","unstructured":"George, E. S. et al. The evidence surrounding non-alcoholic fatty liver disease in individuals with cancer: A systematic literature review. Curr. Oncol. 30, 48\u201374 (2022).","journal-title":"Curr. Oncol."},{"key":"44243_CR21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","volume":"71","author":"AM Allen","year":"2019","unstructured":"Allen, A. M., Hicks, S. B., Mara, K. C., Larson, J. J. & Therneau, T. M. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity\u2014A longitudinal cohort study. J. Hepatol. 71, 1229\u20131236 (2019).","journal-title":"J. Hepatol."},{"key":"44243_CR22","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A. et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies. Gut 71, 778\u2013788 (2022).","journal-title":"Gut"},{"key":"44243_CR23","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.7314\/APJCP.2013.14.5.3117","volume":"14","author":"Q Qin","year":"2013","unstructured":"Qin, Q., Xu, X., Wang, X. & Zheng, X.-Y. Obesity and risk of bladder cancer: A meta-analysis of cohort studies. Asian Pac. J. Cancer Prev. APJCP 14, 3117\u20133121 (2013).","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"44243_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/jcm10020346","volume":"10","author":"G Tarantino","year":"2021","unstructured":"Tarantino, G. et al. Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: A cross-sectional retrospective study. J. Clin. Med. 10, 346 (2021).","journal-title":"J. Clin. Med."},{"key":"44243_CR25","doi-asserted-by":"publisher","first-page":"E86","DOI":"10.1002\/dc.24906","volume":"50","author":"N Narine","year":"2022","unstructured":"Narine, N. et al. Synchronous uterine and bladder cancers detected in urine and vaginal samples by cytology. Diagn. Cytopathol. 50, E86\u2013E91 (2022).","journal-title":"Diagn. Cytopathol."},{"key":"44243_CR26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s12325-017-0556-1","volume":"34","author":"S Ballestri","year":"2017","unstructured":"Ballestri, S. et al. NAFLD as a sexual dimorphic disease: Role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv. Ther. 34, 1291\u20131326 (2017).","journal-title":"Adv. Ther."},{"key":"44243_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/hep.28514","volume":"64","author":"JS Klair","year":"2016","unstructured":"Klair, J. S. et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatol. Baltim. Md 64, 85\u201391 (2016).","journal-title":"Hepatol. Baltim. Md"},{"key":"44243_CR28","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/hep.26761","volume":"59","author":"JD Yang","year":"2014","unstructured":"Yang, J. D. et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 59, 1406\u20131414 (2014).","journal-title":"Hepatology"},{"key":"44243_CR29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.dld.2018.12.024","volume":"51","author":"M-S Kwak","year":"2019","unstructured":"Kwak, M.-S. et al. Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women. Dig. Liver Dis. 51, 1030\u20131035 (2019).","journal-title":"Dig. Liver Dis."},{"key":"44243_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejca.2022.06.051","volume":"173","author":"JA Thomas","year":"2022","unstructured":"Thomas, J. A., Kendall, B. J., Dalais, C., Macdonald, G. A. & Thrift, A. P. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur. J. Cancer 173, 250\u2013262 (2022).","journal-title":"Eur. J. Cancer"},{"key":"44243_CR31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE M\u00f3zes","year":"2022","unstructured":"M\u00f3zes, F. E. et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis. Gut 71, 1006\u20131019 (2022).","journal-title":"Gut"},{"key":"44243_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.kjms.2012.11.007","volume":"29","author":"P-L Tseng","year":"2013","unstructured":"Tseng, P.-L. et al. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J. Med. Sci. 29, 385\u2013395 (2013).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"44243_CR33","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.jhepr.2022.100596","volume":"5","author":"JV Lazarus","year":"2023","unstructured":"Lazarus, J. V. et al. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. JHEP Rep. Innov. Hepatol. 5, 100596 (2023).","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"44243_CR34","doi-asserted-by":"publisher","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel, K. & Sebastiani, G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2, 100067 (2020).","journal-title":"JHEP Rep."},{"key":"44243_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KGMM Alberti","year":"2006","unstructured":"Alberti, K. G. M. M., Zimmet, P. & Shaw, J. Metabolic syndrome\u2014a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. J. Br. Diabet. Assoc. 23, 469\u2013480 (2006).","journal-title":"Diabet. Med. J. Br. Diabet. Assoc."},{"key":"44243_CR36","doi-asserted-by":"publisher","first-page":"101528","DOI":"10.1016\/j.clinre.2020.08.006","volume":"45","author":"C Huang","year":"2021","unstructured":"Huang, C. et al. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease. Clin. Res. Hepatol. Gastroenterol. 45, 101528 (2021).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"44243_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","volume":"30","author":"BK Kim","year":"2010","unstructured":"Kim, B. K. et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. Off. J. Int. Assoc. Study Liver 30, 546\u2013553 (2010).","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"44243_CR38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson, S. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am. J. Gastroenterol. 112, 740\u2013751 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"44243_CR39","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1038\/s41598-017-03589-w","volume":"7","author":"H-W Wang","year":"2017","unstructured":"Wang, H.-W. et al. New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis. Sci. Rep. 7, 3259 (2017).","journal-title":"Sci. Rep."},{"key":"44243_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1874285801913010034","volume":"13","author":"FR Sha","year":"2019","unstructured":"Sha, F. R. et al. Investigating the efficiency of APRI, FIB-4, AAR and AARPRI as noninvasive markers for predicting hepatic fibrosis in chronic hepatitis B Patients in Bangladesh. Open Microbiol. J. 13, 34\u201340 (2019).","journal-title":"Open Microbiol. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44243-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44243-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44243-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:54:32Z","timestamp":1700574872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44243-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44243"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44243-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"25 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17793"}}